-- Poster presentation to highlight data from completed first-in-human, Phase 1 ascending dose clinical trial of ADX-097 in healthy volunteers; results support Phase 2 dose selection and continued ...
Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...
Verywell Health on MSN
Types of complement 3 glomerulopathy: How they differ and what that means
Medically reviewed by Erika Prouty, PharmD Key Takeaways There are two types of complement 3 glomerulopathy: dense deposit ...
SAN DIEGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, today announced positive ...
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-CFB, the ...
The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...
Changes to serum proteins could be behind the debilitating condition known as long COVID. The findings, published in the journal Science, could pave the way for diagnosing and treating the disease.
CNIO researchers identified complement system genes linked to pancreatic cancer susceptibility and prognosis. Mutations in ...
(MENAFN- GlobeNewsWire - Nasdaq) – Single subcutaneous dose of ADX-038 achieved near-complete alternative pathway suppression for 6 months, supporting potent and selective CFB silencing – – Phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback